Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
aTyr Pharma, Inc.
Type
Public company
Traded as
  • NASDAQ: LIFE
Industry Biotechnology,Pharmaceutical
Key people
John Mendlein, CEO
Paul Schimmel, Ph.D., Founder
Xiang-Lei Yang, Ph.D., Founder
Sanuj K. Ravindran, M.D., CBO
Sanjay S. Shukla, M.D., M.S., CMO
Number of employees
67
Website www.atyrpharma.com

aTyr Pharma is a public biotherapeutics company (NASDAQ: LIFE) that researches and develops Physiocrine-based therapeutics for treatment of rare diseases with an immune component. aTyr's key programs are currently focused on severe, rare diseases characterized by immune imbalance for which there are currently limited or no treatment options.

The company’s leading drug candidate, Resolaris is being evaluated in clinical trials for treatment of adult patients with facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy 2B (LGMD2B), and early onset FSHD. Resolaris is thought to halt muscle deterioration by modulating the immune system and promoting tissue homeostasis.

The company was founded in 2005 and is headquartered in San Diego, CA, and led by CEO John Mendlein, Ph.D., J.D.

In 2005, aTyr was founded by Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two aminoacyl tRNA synthetase scientists at The Scripps Research Institute. In 2009, Bruce Beutler, M.D., recipient of the 2011 Nobel Prize in Physiology or Medicine, joined aTyr as a member of the scientific advisory board.

In April 2007, Polaris Partners and Alta Partners co-led a $10.5 million Series B financing. In October 2010, Series C financing totaled $23 million and was led by Domain Associates. This round was followed by a $49 million Series D in August 2013.

aTyr was a winner of the 2011 Red Herring 100 North America Award for discovering and developing innovative medicines based on Physiocrine biology.

In January 2015, aTyr announced its first FSHD patient enrolled in a Phase 1b/2 clinical trial of Resolaris. In February and April of that same year, Resolaris received EMA Orphan Drug Designation and U.S. FDA Orphan Designation for treatment of FSHD.<ref>the pharma letter: EMA Orphan Drug status for aTyr’s Resolaris in FSHD (Feb. 18, 2015)</ref>

In April 2015, aTyr raised $76 million in a Series E, led by Sofinnova Ventures, and filed for an IPO. The company began trading as LIFE on the Nasdaq stock exchange.

In October 2015, aTyr initiated a Phase 1b/2 clinical trial on Resolaris for patients with LGMD2B and the following month initiated a Phase 1b/2 clinical trial in patients with early onset FSHD. aTyr’s second IND candidate, ATYR 1923 (iMod.Fc), was selected in November 2015. ATYR 1923 is an engineered fusion protein. ATYR 1923 was developed for the potential treatment of severe pulmonary diseases with an immune and fibrotic component, including interstitial lung disease.

Throughout 2016 and into the first half of 2017 aTyr released data on three Phase 1b/2 trials for Resolaris in adults with FSHD or LGMD2B, and early onset FSHD patients (ages 16–20). Data from these trials showed encouraging results for safety, tolerability, immunogenicity and pharmacokinetic profile, and signals of clinical activity in regards to muscle strength (Manual Muscle Testing) and disease burden (Individualized Neuromuscular Quality of Life score – INQoL).

Homeostasis, or the coordinated regulation of tissues within the body, is fundamental to the maintenance of the overall health of an organism. Lack of homeostasis can lead to disease and death. The process of homeostasis was first described in 1865 by the French physiologist Claude Bernard and Walter Cannon later coined the term. In the 150 years since this discovery, many proteins associated with homeostatic pathways have been discovered, ranging from insulin to erythropoietin.

aTyr was founded after Dr. Schimmel discovered several nontranslational functions of aminoacyl tRNA synthetases, which are primarily responsible for the production of a vital component of protein synthesis, aminoacyl-tRNAs. [23] These nontranslational functions have since been shown to play an important role in maintaining homeostasis. [23] One of these nontranslational functions is modulation and regulation of the immune response. [23] This modulatory activity is a result of Physiocrines, a novel class of proteins that are present as biologically active signaling regions of the tRNA synthetases. aTyr’s research is based on the premise that Physiocrines are involved in orchestrating homeostatic activities to help the body restore diseased or damaged tissue to a healthier state.

By researching and understanding the role of Physiocrines in immune modulation, aTyr has developed two IND candidates.

Investment goal date:
Dividends reinvested
aTyr Pharma, Inc. LIFE report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-25
--
--
Q4 2017
2018-03-14
--
--
Q3 2017
2017-11-14
--
--
Q3 2017
2017-11-14
-0.4300
0.0000
Q2 2017
2017-11-13
--
--
Q2 2017
2017-08-14
-0.5100
-0.5100
Q1 2017
2017-05-11
-0.5600
-0.5600
Q4 2016
2017-03-16
-0.5300
-0.5300
Q3 2016
2016-11-14
-0.5800
-0.5800
Q2 2016
2016-08-10
-0.6500
-0.6500
Q1 2016
2016-05-11
-0.6800
-0.6800
Q4 2015
2016-03-30
-0.7000
-0.7000
Q3 2015
2015-11-10
-0.4800
-0.4800
Q2 2015
2015-08-12
-0.7400
-0.4900
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Alyeska Investment Group, L.P.
809642
BANK OF AMERICA CORP /DE/
47708
BLACKROCK ADVISORS LLC
211356
BlackRock Inc.
577171
BlackRock Institutional Trust Company, N.A.
354543
BRIDGEWAY CAPITAL MANAGEMENT INC
102697
DIMENSIONAL FUND ADVISORS LP
58172
EcoR1 Capital, LLC
2292659
FMR LLC
3557779
GEODE CAPITAL MANAGEMENT, LLC
112178
JACOBS LEVY EQUITY MANAGEMENT, INC
95074
Polaris Venture Management Co. V, L.L.C.
1827992
RIVERHEAD CAPITAL MANAGEMENT LLC
79677
Rock Springs Capital Management LP
475000
Vanguard Group, Inc
435324
Major Shareholders
Name Relationship
Total Shares
Holding stocks
LEVINE ARNOLD J
0.0100% (21735)
INFI / LIFE / THRX /
% ()